Cargando…
Clozapine and Neutropenia in Patients with Schizophrenia and SARS-CoV-2 Infection
BACKGROUND: Clozapine (CLZ) is used for treatment-resistant schizophrenia (TRS). Adverse reactions to clozapine include neutropenia. In March 2020, WHO declared the COVID-19 pandemic and after, psychiatrists raised concerns regarding continuation of clozapine, due to multiple restrictions. We aimed...
Autores principales: | , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Dove
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9081886/ https://www.ncbi.nlm.nih.gov/pubmed/35547265 http://dx.doi.org/10.2147/NDT.S361405 |
_version_ | 1784703091775373312 |
---|---|
author | Moga, Silvia Teodorescu, Andreea Ifteni, Petru Petric, Paula-Simina Miron, Ana-Aliana |
author_facet | Moga, Silvia Teodorescu, Andreea Ifteni, Petru Petric, Paula-Simina Miron, Ana-Aliana |
author_sort | Moga, Silvia |
collection | PubMed |
description | BACKGROUND: Clozapine (CLZ) is used for treatment-resistant schizophrenia (TRS). Adverse reactions to clozapine include neutropenia. In March 2020, WHO declared the COVID-19 pandemic and after, psychiatrists raised concerns regarding continuation of clozapine, due to multiple restrictions. We aimed to provide a study on the association between neutropenia and clozapine in patients with schizophrenia and COVID-19. AIM: To assess the neutrophil count in patients with schizophrenia treated with clozapine and infected with COVID-19. METHODS: The study patients with schizophrenia, according to DSM-5, admitted to the Clinical Hospital of Psychiatry and Neurology Brasov, Romania, between April 2020 and October 2021. The inclusion criteria included positive RT-PCR (real-time PCR) test for COVID-19 and treatment with clozapine. We assessed three values of ANC (absolute neutrophil count): before COVID-19 infection (last ANC obtained at mandatory check), during infection and 1 month after resolution (first negative PCR test). RESULTS: Of the 105 cases, 95 did not have neutropenia. Fifty-nine patients were males (62.1%), mean age was 43.5 years (SD = 12.1) with an average of clozapine treatment of 52.4 months (SD = 11.9). At baseline, they had a small reduction in the ANC mean value (4.41 × 109/l; SD = 2.22) which did not constitute a statistically significant decline from the prior to COVID-19 mean value of 4.66 × 109/l (SD = 2.34; p = 0.45). Values were also normal in the first month after negative PCR testing (4.45 × 109/l; SD = 2.35; p = 0.91). A total of 10 patients (9.5%) had neutropenia. The age, dose of clozapine and duration of treatment were not statistically different compared to the group without neutropenia. CONCLUSION: Psychiatrists and other health professionals should keep in mind that neutrophil count may decrease during COVID-19 infection in patients taking clozapine and in some cases, neutropenia may even occur. We assumed that neutropenia could be caused by COVID-19 and clozapine interaction. |
format | Online Article Text |
id | pubmed-9081886 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | Dove |
record_format | MEDLINE/PubMed |
spelling | pubmed-90818862022-05-10 Clozapine and Neutropenia in Patients with Schizophrenia and SARS-CoV-2 Infection Moga, Silvia Teodorescu, Andreea Ifteni, Petru Petric, Paula-Simina Miron, Ana-Aliana Neuropsychiatr Dis Treat Original Research BACKGROUND: Clozapine (CLZ) is used for treatment-resistant schizophrenia (TRS). Adverse reactions to clozapine include neutropenia. In March 2020, WHO declared the COVID-19 pandemic and after, psychiatrists raised concerns regarding continuation of clozapine, due to multiple restrictions. We aimed to provide a study on the association between neutropenia and clozapine in patients with schizophrenia and COVID-19. AIM: To assess the neutrophil count in patients with schizophrenia treated with clozapine and infected with COVID-19. METHODS: The study patients with schizophrenia, according to DSM-5, admitted to the Clinical Hospital of Psychiatry and Neurology Brasov, Romania, between April 2020 and October 2021. The inclusion criteria included positive RT-PCR (real-time PCR) test for COVID-19 and treatment with clozapine. We assessed three values of ANC (absolute neutrophil count): before COVID-19 infection (last ANC obtained at mandatory check), during infection and 1 month after resolution (first negative PCR test). RESULTS: Of the 105 cases, 95 did not have neutropenia. Fifty-nine patients were males (62.1%), mean age was 43.5 years (SD = 12.1) with an average of clozapine treatment of 52.4 months (SD = 11.9). At baseline, they had a small reduction in the ANC mean value (4.41 × 109/l; SD = 2.22) which did not constitute a statistically significant decline from the prior to COVID-19 mean value of 4.66 × 109/l (SD = 2.34; p = 0.45). Values were also normal in the first month after negative PCR testing (4.45 × 109/l; SD = 2.35; p = 0.91). A total of 10 patients (9.5%) had neutropenia. The age, dose of clozapine and duration of treatment were not statistically different compared to the group without neutropenia. CONCLUSION: Psychiatrists and other health professionals should keep in mind that neutrophil count may decrease during COVID-19 infection in patients taking clozapine and in some cases, neutropenia may even occur. We assumed that neutropenia could be caused by COVID-19 and clozapine interaction. Dove 2022-05-04 /pmc/articles/PMC9081886/ /pubmed/35547265 http://dx.doi.org/10.2147/NDT.S361405 Text en © 2022 Moga et al. https://creativecommons.org/licenses/by-nc/3.0/This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/ (https://creativecommons.org/licenses/by-nc/3.0/) ). By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms (https://www.dovepress.com/terms.php). |
spellingShingle | Original Research Moga, Silvia Teodorescu, Andreea Ifteni, Petru Petric, Paula-Simina Miron, Ana-Aliana Clozapine and Neutropenia in Patients with Schizophrenia and SARS-CoV-2 Infection |
title | Clozapine and Neutropenia in Patients with Schizophrenia and SARS-CoV-2 Infection |
title_full | Clozapine and Neutropenia in Patients with Schizophrenia and SARS-CoV-2 Infection |
title_fullStr | Clozapine and Neutropenia in Patients with Schizophrenia and SARS-CoV-2 Infection |
title_full_unstemmed | Clozapine and Neutropenia in Patients with Schizophrenia and SARS-CoV-2 Infection |
title_short | Clozapine and Neutropenia in Patients with Schizophrenia and SARS-CoV-2 Infection |
title_sort | clozapine and neutropenia in patients with schizophrenia and sars-cov-2 infection |
topic | Original Research |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9081886/ https://www.ncbi.nlm.nih.gov/pubmed/35547265 http://dx.doi.org/10.2147/NDT.S361405 |
work_keys_str_mv | AT mogasilvia clozapineandneutropeniainpatientswithschizophreniaandsarscov2infection AT teodorescuandreea clozapineandneutropeniainpatientswithschizophreniaandsarscov2infection AT iftenipetru clozapineandneutropeniainpatientswithschizophreniaandsarscov2infection AT petricpaulasimina clozapineandneutropeniainpatientswithschizophreniaandsarscov2infection AT mironanaaliana clozapineandneutropeniainpatientswithschizophreniaandsarscov2infection |